Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Bortezomib & Mycophenolate mofetil

Status:

Phase 2

Condition:

Systemic Sclerosis ILD

Intervention Type:

Intravenous (IV) Injection

Funder Type:

Organization | University

Drug Details

Bortezomib is an FDA approved therapy for the treatment of multiple myeloma and other malignancies.

Mycophenolate mofetil (CellCept or Myfortic) belongs to a class of medications known as immunosuppressives. This medication was used originally in the management of patients with organ transplants, but is now recommended in the treatment of some autoimmune diseases such as SSc.

Study Purpose

The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.

This drug has no clinical trials actively recruiting patients at this time.